Robert I. Blum, President and CEO of Cytokinetics Inc., filed a Form 4 on August 31, 2026, disclosing the exercise of a stock option and same-day sale of 7,500 shares of common stock pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Option exercise: Blum acquired 7,500 shares of common stock on August 31, 2026, via a non-qualified stock option at an exercise price of $10.60 per share.
  • Shares sold: 7,500 shares of common stock were disposed of on August 31, 2026, at a price of $70.24 per share.
  • Remaining direct ownership: Following the transactions, Blum directly held 377,820 shares of common stock.
  • Indirect holdings: An additional 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust, and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
  • Derivative securities: After the exercise, Blum retained 164,245 non-qualified stock options with an exercise price of $10.60 and an expiration date of February 28, 2027.
  • Rule 10b5-1 plan: The filing indicates the transactions were made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).

Blum's Option Exercise and Sale Transaction Details at Cytokinetics

According to the Form 4 filed with the SEC on August 31, 2026, Robert I. Blum, who serves as both a Director and President and CEO of Cytokinetics Inc. (NASDAQ:CYTK), exercised a non-qualified stock option covering 7,500 shares of common stock. The option carried a conversion price of $10.60 per share and was originally dated with an exercisable date of March 28, 2017, and an expiration date of February 28, 2027. The filing records the price of the derivative security upon exercise as $0.

On the same date, August 31, 2026, Blum disposed of 7,500 shares at a price of $70.24 per share, according to the filing. Following these transactions, his direct beneficial ownership stands at 377,820 shares of common stock. The filing also shows indirect holdings of 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

The Form 4 indicates that the transactions were executed pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The filing was signed by John O. Faurescu as attorney-in-fact for Mr. Blum on August 31, 2026. After the option exercise, Blum retained 164,245 non-qualified stock options directly held, according to the filing.

What Was Disclosed

The filing reported a same-day option exercise and share sale by Cytokinetics' President and CEO on August 31, 2026, conducted under a Rule 10b5-1 plan, with resulting direct ownership of 377,820 shares and 164,245 remaining stock options.